Explore Business Standard
Associate Sponsors
Co-sponsor
GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies for gynaecological cancers. The company has introduced advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in the country. "These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women's cancer care. With this launch, we are strengthening our long-term commitment to build the specialty medicine portfolio in India," GSK India MD Bhushan Akshikar said in a statement. Gynaecological cancers are among the most common cancers in women in India. By 2045, the incidence of endometrial and ovarian cancer in India is projected to increase by 78 per cent and 69 per cent, respectively. Endometrial cancer is a malignancy arising out of the endometrium, the inner lining of the uterus. Nearly a fourth of endometrial cancer patients in India are at an advanced stage where chemotherapy remains a standa
A study released to coincide with Women's Health Month, is shedding light on how robotic-assisted surgery (RAS) is steadily transforming gynaecological care across the country. May month is observed as Women's Health Month worldwide, to focus on raising awareness about women's health issues and encouraging women to prioritise their physical, mental, and emotional well-being. "Women's Health Month is a time to reflect on how surgical technology innovations like the da Vinci robotic technology are enhancing healthcare outcomes for women," said Dr Rooma Sinha, Honorary Professor and Chief Gynaecologist at Apollo Health City, Hyderabad, one of the surgeons who oversaw the study. The multi-institutional study, 'Trends in Gynaecological Robotic Surgery in India: A Real-World Scenario', was conducted across five tertiary care hospitals -- Apollo Health City (Hyderabad), PGIMER (Chandigarh), Manipal Hospital (Bengaluru), Narayana Health (Bengaluru), and Tata Memorial Hospital (Mumbai). It